Thesis (Ph.D.)--University of Adelaide, Dept. of Chemistry, 2001. / Bibliography: leaves 178-195.

Thèses (M.Sc.)--Université de Sherbrooke (Canada), 2004. / Titre de l'écran-titre (visionné le 20 juin 2006). Publié aussi en version papier.

Thesis (M.S.)--Georgia State University, 2009. / Title from file title page. W. David Wilson, committee chair; Stewart A. Allison, Kathryn B. Grant, committee members. College of Arts and Sciences.Description based on contents viewed July 22, 2009. Includes bibliographical references (p. 85-87).

The development and approval of new drugs is an expensive process. The total cost for the approval of a new compound is on average 1.0 - 1.2 billion dollars and the entire process lasts about 12 - 15 years. The main difficulties are related to poor pharmacokinetics, lack of efficacy and unwanted side effects. These problems have naturally led to the question if new and alternative methodologies can be developed to find reliable and low cost alternatives to existing practices. Nowadays, computer-assisted tools are used to support the decision process along the early stages of the drug discovery path leading from the identification of a suitable biomolecular target to the design/optimization of drug-like molecules. This process includes assessments about target druggability, screening of molecular libraries and the optimization of lead compounds where new drug-like molecules able to bind with sufficiently affinity and specificity to a disease-involved protein are designed. Existing computational methods used by the pharmaceutical industry are usually focused on the screening of library compounds such as docking, chemoinformatics and other ligand-based methods to predict and improve binding affinities, but their reliable application requires improvements in accuracy. New quantitative methods based on molecular simulations of drug binding to a protein could greatly improve prospects for the reliable in-silico design of new potent drug candidates. A common parameter used by medicinal chemists to quantify the affinity between candidate ligands and a target protein is represented by the free energy of binding. However, despite the increased amount of structural information, predicting binding free energy is still a challenge and this technique has found limited use beyond academia. A major reason for limited adoption in the industry is that reliable computer models of drug binding to a protein must reproduce the change in molecular conformations of the drug and protein upon complex formation and this includes the correct modelling of weak non-covalent interactions such as hydrogen bonds, burials of hydrophobic surface areas, Van der Waals interactions, fixations of molecular degrees of freedom solvation/desolvation of polar groups and different entropy contributions related to the solvent and protein interactions. For several classes of proteins these phenomena are not easy to model and often require extremely computationally intensive simulations. The main goal of the thesis was to explore efficient ways of computing binding affinities by using molecular simulations. With this aim, novel software to compute relative binding free energies has been developed. The implementation is based on alchemical transformations and it extended a preexisted piece of software Sire, a molecular modeling framework, by using the OpenMM APIs to run fast molecular dynamics simulations on the latest GPGPU technology. This new piece of software has equipped the scientific community with a flexible and fast tool, not only to predict relative binding affinities, but also a starting point to develop new sampling methods for instance hybrid molecular dynamics and Monte Carlo. The implementation has been validated on the prediction of relative hydration free energy of small molecules, showing good agreement with experimental data. In addition, non-additive effects to binding affinities in series of congeneric Thrombin inhibitors were investigated. Although excellent agreement between predicted and experimental relative binding affinities was achieved, it was not possible to accurately predict the non-additivity levels in most of the examined inhibitors, thus suggesting that improved force fields are required to further advance the state-of-the art of the field.

Cancer results from the accumulation of genetic mutations in a normal cell that ultimately result in the expression (or overexpression) of oncogenes. The design of drugs having high affinity for specific DNA sequences or structural motifs is vital to gaining a better understanding of gene expression and to the development of new cancer treatments that are based on turning off oncogene expression. This dissertation presents studies of the binding of two ligand families, Berenil (DMZ), and ruthenium polypyridyl complexes (RPCs), to B-DNA and G-quadruplex (G4) DNA. The structureunction relationships for the interaction of these ligand families with DNA were probed by functional group substitution, truncation, or modification of the DMZ amidine groups, and by changing one of the RPC ruthenium ligands from phenanthroline to dipyridophenazine (dppz) or tetraazatetrapyrido-pentacene (tatpp), and lastly by adding a second Ru(Phen)2 core to the tatpp bridging ligand. Removal of one or both amidine groups from DMZ drastically reduces its binding to both B-DNA and G4-DNA. DMZ analogs in which one amidine was replaced by an alkyne group were synthesized with the expectation that the additional π-bonding character of the alkyne group would increase G4 affinity. All of the DMZ alkyne compounds were found to bind preferentially to G4-DNA (over B-DNA) and a few of these compounds demonstrated significant anticancer activity. RPCs with progressively longer ruthenium bound ligands were found to bind with differing affinities to B-DNA and G4-DNA. Monoruthenium RPCs exhibited a preference for binding to B-DNA, while binding the diruthenium RPC to G4-DNA was more complicated exhibiting both tighter and a weaker binding modes in comparison to the B-DNA complex. The diruthenium complex was found to bind more tightly to G4-DNA by approximately 3 kcal mol-1. The binding of small molecules to DNA resulting in the disruption of oncogene transcription represents a powerful approach to the treatment of cancer.

A modelagem das interações entre macromoléculas e ligantes ainda se depara com diversos desafios na área de desenho de fármacos assistidos por computador. Apesar do crescimento da área, temas como a flexibilidade do receptor, funções de pontuação e solvatação ainda têm sido alvo de intensa investigação na comunidade científica. Com o objetivo de analisar a interação em milhares ou milhões de complexos, é imprescindível uma boa harmonização entre o custo computacional e a acurácia dos métodos computacionais que permitem a classificação de ligantes de acordo com a energia de interação. O LiBELa (Ligand Binding Energy Landscape) é um programa de docagem molecular com abordagem híbrida, ou seja, utiliza informações do ligante e do receptor durante o processo de docagem. Inicialmente, as características estéricas e eletrostáticas de um ligante de referência (cristalográfico, por exemplo) são utilizadas nos cálculos de similaridade e sobreposição, obtendo assim uma conformação inicial pré-otimizada do ligante testado. Em seguida, a energia de interação é minimizada no sítio ativo de receptor a partir de potenciais energéticos. Quatro funções de pontuação baseadas em campo de força foram testadas e otimizadas, compostas por potenciais de van der Waals, de Coulomb, e uma função empírica de solvatação denominada função de Stouten-Verkhivker (SV). A flexibilidade do sistema foi tratada através da geração de confôrmeros que amostram os graus de liberdade dos ligantes descritos como semi-rígidos e através de potenciais atenuados que suavizam a superfície de energia de interação, permitindo interações em distâncias interatômicas antes repulsivas. Como ponto de partida, os métodos implementados no programa LiBELa demonstraram resultados satisfatórios nos testes de cross- e self-docking, mostrando ser uma ferramenta eficiente em encontrar os modos de ligação cristalográficos de forma equivalente ou até melhor às dos programas comparados. Através de testes de enriquecimento nos conjuntos de dados DUD, DUDE e CM-DUD, foram otimizadas de forma sistemática as constantes dielétrica, do termo de solvatação, e dos termos de atenuação. Também foi realizado um paralelo entre as funções de pontuação, incluindo a atenuação e o termo de solvatação. Estes mesmos testes mostraram resultados superiores do LiBELa de 39% e 15% em comparação com um programa baseado puramente no receptor (DOCK 6.6), relativo à média da área sob a curva em escala semi-logarítmica nas bases de dados DUDE e DUD respectivamente. Apesar da função de solvatação SV implementada no LiBELa apresentar boa correlação com dados experimentais (r=0,72) e com o modelo Zou GB de solvatação (r=0,88), não apresentou correlação significativa com os métodos GB e PB implementados no pacote de programas disponível no AmberTools. Comparadas às funções de pontuação do LiBELa, as funções com correção para solvatação apresentaram pior enriquecimento, salvo alguns alvos específicos. Por fim, foram realizados ensaios de docagem molecular utilizando como alvo uma enzima β-galactosidase da família GH42, cuja estrutura fora resolvida em nosso grupo. Os resultados permitiram conclusões acerca de como o modo de ligação interfere na preferência de ligação entre dissacarídeos de ligações glicosídicas distintas, consistentes com dados experimentais de ensaios cinéticos de ligação. / Modeling the interactions between macromolecules and ligands still faces several challenges in the computer-aided drug design area. Despite the growth in the area, subjects such as receptor flexibility, scoring functions and solvation still have been widely explored in the scientific community. In order to analyze the interaction for thousands or millions of complexes, a good harmonization between the computational cost and the accuracy of the calculation methods in molecular docking programs is essential. LiBELa (Ligand Binding Energy Landscape) is a hybrid approach program that uses both ligand and receptor information for ligand docking. Initially, the steric and electrostatic characteristics from a reference binder (crystallographic, for example) are used to similarity and overlay calculations, thus obtaining an initial conformation of the ligand tested. Then, within the receptor´s active site, the interaction energy is minimized using energetic potentials. Four force field-based scoring functions were tested and optimized, composed of van der Waals and Coulomb potentials and an empirical solvation function called Stouten-Verkhivker (SV). Concerning the system flexibility, besides the confomers generation that sample the degrees of freedom for semi-rigid ligands, attenuated potentials smooth the energy surface allowing interactions between previously repulsive interatomic distances. As a starting point, LiBELa performed satisfactorily in the cross- and self-docking tests, showing that is an eficient tool to reproduce crystallographic binding modes equivalently to or even better than reference programs. Through enrichment of DUD, DUDE and CM-DUD datasets, the dielectric constant, solvation and softening terms were systematically optimized. It also allowed a parallel between scoring functions, including attenuation and solvation term. Finally, it revealed the LiBELa showed an enhancement of 39% and 15% as compared to the purely receptor-based program DOCK 6.6, relative to the mean of the area under the curve on a semi-logarithmic scale in the DUDE and DUD databases respectively. Although the SV solvation function implemented in LiBELa showed good correlations with experimental data (r = 0.72) and with the Zou GB / SA solvation method implemented in DOCK6 (r = 0.88), it did not show significant correlation with the GB/SA and PB/SA methods implemented in AmberTools. Comparing all the LiBELa tested scoring functions, those including solvation correction showed worse enrichments, except for some specific targets. Finally, molecular docking experiments using LiBELa were conducted with a β-galactosidase from GH42 family, whose structure was solved in our group. The results allowed conclusions concerning how the binding mode interferes the preference for some disaccharides of distinct glycosidic bonds, consistent with experimental data from kinetic assays.

Bibliography: leaves 178-195.

This thesis reports the synthesis, characterisation and DNA binding of a number of novel ruthenium(II) complexes. Four mononuclear complexes were synthesised. These complexes were resolved using a large scale extraction procedure employing the chiral TRISPHAT anion. The racemic mononuclear complexes containing halogenated ligands were used in the synthesis of the racemic dinuclear complexes. Resolved mononuclear complexes were also used to stereo-selectively synthesise enantiomers of their respective dinuclear complexes. All metal complexes were characterised using fluorescence spectroscopy. Resolved metal complexes were further characterised using CD spectroscopy to determine their molar rotation coefficients and optical purity. Preliminary DNA binding studies were conducted using the racemic dinuclear complexes and their mononuclear equivalent. Titration experiments with calf thymus-DNA were used to determine the DNA binding constant and binding site size. Samples containing a higher NaCl concentration (100 mM) slightly improved the oligonucleotide spectrum resolution, but not to an extent where a complex binding model could be determined. Attempts to determine DNA binding preferences of the dinuclear complexes with oligonucleotides which contain two-adenine bulge sites using a 96-well a fluorescence plate reader were attempted, but were unsuccessful. Samples containing a higher NaCl concentration (100 mM) slightly improved the oligonucleotide spectrum resolution, but not to an extent where a complex binding model could be determined. Attempts to determine DNA binding preferences of the dinuclear complexes with oligonucleotides which contain two-adenine bulge sites using a 96-well a fluorescence plate reader were attempted, but were unsuccessful. / Doctor of Philosophy (PhD)

Bibliography: leaves 178-195. / xiv, 195 leaves : ill. ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, Dept. of Chemistry, 2001

"January 2004" / Bibliography: leaves 163-184. / v, 184 leaves : ill. (some col.), photos ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, School of Chemistry and Physics, Discipline of Chemistry, 2004